AMP kinase (PRKAA1)

Journal of Clinical Pathology

Volumn 67, Issue 9, 2014, Pages 758-763

  Krishan, Sukriti ^a   Richardson, Des R ^a   Sahni, Sumit ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; ENZYME ACTIVATOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PRKAA1 PROTEIN, HUMAN;

ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; DEGENERATIVE DISEASE; DIABETES MELLITUS; ENERGY BALANCE; ENERGY CONSUMPTION; ENERGY METABOLISM; ENZYME ACTIVATION; GENE; HEART VENTRICLE HYPERTROPHY; HUMAN; METASTASIS INHIBITION; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PRKAA1 GENE; SYNTHESIS; ANIMAL; CARDIOMEGALY; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIOMEGALY; DIABETES MELLITUS; DRUG DESIGN; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVATORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEURODEGENERATIVE DISEASES; SIGNAL TRANSDUCTION;

EID: 84906940287     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202422     Document Type: Article

References (84)

1. Huang FY, Chiu PM, Tam KF, et al. Semi-quantitative fluorescent PCR analysis identifies PRKAA1 on chromosome 5 as a potential candidate cancer gene of cervical cancer. Gynecol Oncol 2006;103:219-25. (Pubitemid 44374692)
2. Carling D, Thornton C, Woods A, et al. AMP-activated protein kinase: new regulation, new roles? Biochem J 2012;445:11-27.
3. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007;8:774-85. (Pubitemid 47462132)
4. Carling D, Clarke PR, Zammit VA, et al. Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem 1989;186:129-36. (Pubitemid 20015135)
5. Cheung PC, Salt IP, Davies SP, et al. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 2000;346:659-69. (Pubitemid 30171026)
6. Sullivan JE, Carey F, Carling D, et al. Characterisation of 5′-AMP-activated protein kinase in human liver using specific peptide substrates and the effects of 5′-AMP analogues on enzyme activity. Biochem Biophys Res Commun 1994;200:1551-6.
7. Davies SP, Helps NR, Cohen PT, et al. 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett 1995;377:421-5. (Pubitemid 26027159)
8. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003;13:2004-8. (Pubitemid 37425212)
9. Anderson KA, Ribar TJ, Lin F, et al. Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab 2008;7:377-88. (Pubitemid 351598022)
10. Green MF, Anderson KA, Means AR. Characterization of the CaMKKbeta-AMPK signaling complex. Cell Signal 2011;23:2005-12.
11. Momcilovic M, Hong S-P, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem 2006;281:25336-43. (Pubitemid 44401921)
12. Hardie DG. Regulation of fatty acid synthesis via phosphorylation of acetyl-CoA carboxylase. Prog Lipid Res 1989;28:117-46.
13. Habegger KM, Hoffman NJ, Ridenour CM, et al. AMPK enhances insulin-stimulated GLUT4 regulation via lowering membrane cholesterol. Endocrinology 2012;153:2130-41.
14. Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011;13:132-41.
15. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009;9:563-75.
16. Marcus AI, Zhou W. LKB1 regulated pathways in lung cancer invasion and metastasis. J Thorac Oncol 2010;5:1883-6.
17. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 2002;30:1064-70. (Pubitemid 36002407)
18. Bianchi A, Evans JL, Iverson AJ, et al. Identification of an isozymic form of acetyl-CoA carboxylase. J Biol Chem 1990;265:1502-9.
19. Thampy KG. Formation of malonyl coenzyme A in rat heart. Identification and purification of an isozyme of A carboxylase from rat heart. J Biol Chem 1989;264:17631-4. (Pubitemid 19279218)
20. Wakil SJ, Titchener EB, Gibson DM. Evidence for the participation of biotin in the enzymic synthesis of fatty acids. Biochim Biophys Acta 1958;29:225-6.
21. Bremer J. Carnitine in intermediary metabolism. The biosynthesis of palmitylcarnitine by cell subfractions. J Biol Chem 1963;238:2774-9.
22. Fritz IB, Yue KT. Long-chain carnitine acyltransferase and the role of acylcarnitine derivatives in the catalytic increase of fatty acid oxidation induced by carnitine. J Lipid Res 1963;4:279-88.
23. Kudo N, Barr AJ, Barr RL, et al. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 1995;270:17513-20.
24. Lopaschuk GD, Gamble J. The 1993 Merck Frosst Award. Acetyl-CoA carboxylase: an important regulator of fatty acid oxidation in the heart. Can J Physiol Pharmacol 1994;72:1101-9.
25. Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011;13:376-88.
26. Karuman P, Gozani O, Odze RD, et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell 2001;7:1307-19. (Pubitemid 32607363)
27. Foretz M, Guichard C, Ferre P, et al. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci USA 1999;96:12737-42. (Pubitemid 29513572)
28. Choi KS. Autophagy and cancer. Exp Mol Med 2012;44:109-20.
29. Rosenfeldt MT, Ryan KM. The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med 2009;11:e36.
30. Young AR, Chan EY, Hu XW, et al. Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes. J Cell Sci 2006;119:3888-900. (Pubitemid 44614440)
31. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45. (Pubitemid 39071573)
32. Holz MK, Ballif BA, Gygi SP, et al. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005;123:569-80. (Pubitemid 41608461)
33. Haghighat A, Mader S, Pause A, et al. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J 1995;14:5701.
34. Sonenberg N, Gingras A-C. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998;10:268-75. (Pubitemid 28174770)
35. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. (Pubitemid 47001784)
36. Dan HC, Sun M, Yang L, et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 2002;277:35364-70.
37. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009;196:65-80.
38. Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer. Oncogene 2013;32:3923-32.
39. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011;36:320-8.
40. Inoki K, Li Y, Xu T, et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003;17:1829-34. (Pubitemid 36944560)
41. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91-9. (Pubitemid 38903165)
42. Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 2007;25:903-15. (Pubitemid 46436534)
43. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008;30:214-26. (Pubitemid 351626684)
44. Nakano A, Kato H, Watanabe T, et al. AMPK controls the speed of microtubule polymerization and directional cell migration through CLIP-170 phosphorylation. Nat Cell Biol 2010;12:583-90.
45. Dragestein KA, van Cappellen WA, van Haren J, et al. Dynamic behavior of GFP-CLIP-170 reveals fast protein turnover on microtubule plus ends. J Cell Biol 2008;180:729-37. (Pubitemid 351397772)
46. Sawin KE, Nurse P. Regulation of cell polarity by microtubules in fission yeast. J Cell Biol 1998;142:457-71. (Pubitemid 28361552)
47. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009;9:407-16.
48. Winder W, Hardie D. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 1999;277:E1-E10. (Pubitemid 29356721)
49. Frayn KN, Coppack SW, Humphreys SM, et al. Periprandial regulation of lipid metabolism in insulin-treated diabetes mellitus. Metabolism 1993;42:504-10. (Pubitemid 23112718)
50. Cushman S, Goodyear L, Pilch P, et al. Molecular mechanisms involved in GLUT4 translocation in muscle during insulin and contraction stimulation. Adv Exp Med Biol. 1998;441:63-71. (Pubitemid 28428980)
51. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, et al. 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 1999;48:1667-71. (Pubitemid 29356879)
52. Bergeron R, Russell RR III, Young LH, et al. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol 1999;276:E938-44. (Pubitemid 29249614)
53. Halseth AE, Ensor NJ, White TA, et al. Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. Biochem Biophys Res Commun 2002;294:798-805. (Pubitemid 34687187)
54. Song XM, Fiedler M, Galuska D, et al. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 2002;45:56-65. (Pubitemid 34118543)
55. Yu X, McCorkle S, Wang M, et al. Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia 2004;47:2012-21. (Pubitemid 40110213)
56. de Souza CJ, Yu JH, Robinson DD, et al. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. Diabetes 1995;44:984-91.
57. Matthaei S, Reibold JP, Hamann A, et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology 1993;133:304-11. (Pubitemid 23206408)
58. Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003;2:28.
59. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004;101:3329-35. (Pubitemid 38338195)
60. Imamura K, Ogura T, Kishimoto A, et al. Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 2001;287:562-7. (Pubitemid 32917636)
61. Jones RG, Plas DR, Kubek S, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005;18:283-93. (Pubitemid 41350534)
62. Luo Z, Zang M, Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010;6:457-70.
63. Saxena NK, Sharma D. Metastasis suppression by adiponectin: LKB1 rises up to the challenge. Cell Adh Migr 2010;4:358-62.
64. Shaw RJ. Tumor suppression by LKB1: SIK-ness prevents metastasis. Sci Signal 2009;2:pe55.
65. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta 2009;1796:293-308.
66. Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 2008;1778:660-9.
67. Royer C, Lu X. Epithelial cell polarity: a major gatekeeper against cancer&quest. Cell Death Different 2011;18:1470-77.
68. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008;22:999-1012.
69. Tillhon M, Guaman Ortiz LM, Lombardi P, et al. Berberine: new perspectives for old remedies. Biochem Pharmacol 2012;84:1260-7.
70. Singh T, Vaid M, Katiyar N, et al. Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E(2) and prostaglandin E(2) receptors. Carcinogenesis 2011;32:86-92.
71. Park JJ, Seo SM, Kim EJ, et al. Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin beta1 signaling. Biochem Biophys Res Commun 2012;426:461-7.
72. Kim HS, Kim MJ, Kim EJ, et al. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol 2012;83:385-94.
73. Muller-Decker K, Furstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog 2007;46:705-10. (Pubitemid 47255191)
74. Allard MF, Schonekess BO, Henning SL, et al. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 1994;267:H742-50. (Pubitemid 24272494)
75. Nascimben L, Ingwall JS, Lorell BH, et al. Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension 2004;44:662-7. (Pubitemid 39435236)
76. Stuck BJ, Lenski M, Bohm M, et al. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J Biol Chem 2008;283:32562-9.
77. Fassett JT, Hu X, Xu X, et al. AMPK attenuates microtubule proliferation in cardiac hypertrophy. Am J Physiol 2013;304:H749-58.
78. Zhang P, Hu X, Xu X, et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008;52:918-24.
79. Chan AY, Soltys CL, Young ME, et al. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 2004;279:32771-9. (Pubitemid 39014736)
80. Vilchez D, Ros S, Cifuentes D, et al. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat Neurosci 2007;10:1407-13. (Pubitemid 350014686)
81. Tschape JA, Bettencourt da Cruz A, Kretzschmar D. Progressive neurodegeneration in Drosophila: a model system. J Neural Transm Suppl 2003:51-62. (Pubitemid 38339947)
82. Spasic MR, Callaerts P, Norga KK. Drosophila alicorn is a neuronal maintenance factor protecting against activity-induced retinal degeneration. J Neurosci 2008;28:6419-29.
83. Kuramoto N, Wilkins ME, Fairfax BP, et al. Phospho-dependent functional modulation of GABA(B) receptors by the metabolic sensor AMP-dependent protein kinase. Neuron 2007;53:233-47. (Pubitemid 46074400)
84. Ito M, Yoshida M, Obata K, et al. Inhibitory control of intracerebellar nuclei by the Purkinje cell axons. Exp Brain Res 1970;10:64-80.